07:00 , Sep 5, 2011 |  BC Week In Review  |  Company News

Ardelyx management update

Ardelyx Inc. , Fremont, Calif.   Business: Gastrointestinal, Renal   Hired: Mark Kaufmann as CBO, a newly created position, formerly president and CEO of Allostera Pharma Inc.  ...
00:03 , Sep 1, 2011 |  BC Extra  |  Financial News

Ardelyx tops off B round with $12.4 million

Ardelyx Inc. (Fremont, Calif.) raised an additional $12.4 million in a series B round, bringing the total raised in the round to $30 million. New Investor Amgen Ventures joined existing investors New Enterprise Associates and...
07:00 , Jul 15, 2010 |  BC Innovations  |  Targets & Mechanisms

IL-1 receptor antagonists in ALS

Researchers at the Max Planck Institute for Infection Biology have shown that inhibiting the IL-1 receptor improves survival in a mouse model of familial amyotrophic lateral sclerosis. 1 Although efficacy results in mouse models of...
07:00 , May 24, 2010 |  BC Week In Review  |  Company News

Allostera board of directors update

Allostera Pharma Inc. , Montreal, Quebec   Business: Autoimmune, Inflammation, Cancer   Appointed: Christopher Henney, current chairman of Oncothyreon Inc. and Anthera Pharmaceuticals Inc. , as chairman  ...
07:00 , Jul 13, 2009 |  BC Week In Review  |  Financial News

Allostera completes venture financing

Allostera Pharma Inc. , Montreal, Quebec   Business: Cancer, Autoimmune   Date completed: 7/8/09   Type: Venture financing   Raised: C$17 million (US$14.6 million)   Investors: iNovia Capital; Genesys Capital Partners; BDC Venture Capital with...
07:00 , Mar 12, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Multiple myeloma (MM) Insulin-like growth factor 1 (IGF1); IGF1 receptor (IGF1R); IL-6; IL-6 receptor (IL-6R) Studies in patient samples and in...